4
Changes in Ownership
Fulcrum Therapeutics, Inc. Filed Acc 0000899243-21-032755
Chief Scientific Officer sold 51,785 shares at an average $17.60 ($911,416)
- Chief Scientific Officer acquired 51,785 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Moxham Christopher · Chief Scientific Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-08-10 | Exercise or conversion : show line 1 in the form | +20,714 | $7.84 | $162,398 | 20,714 | D |
| 2021-08-10 | Sale : show line 2 in the form | −20,714 | $17.00 | $352,138 | 0 | D |
| 2021-08-10 | Exercise or conversion : show line 3 in the form | +31,071 | $7.84 | $243,597 | 31,071 | D |
| 2021-08-10 | Sale : show line 4 in the form | −31,071 | $18.00 | $559,278 | 0 | D |
| Open-market sales · 51,785 sh · avg $17.60 · $911,416 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2021-08-10 | Exercise or conversion : show line 5 in the form Stock Option (right to buy) | −20,714 | 103,572 | D |
| 2021-08-10 | Exercise or conversion : show line 6 in the form Stock Option (right to buy) | −31,071 | 72,501 | D |
Loading xslF345X03/doc4.xml…